
Claims

1. A granular pharmaceutical composition comprising a compound of formula (I)



I

or a pharmaceutically acceptable salt thereof and at least one poloxamer.

~~2. The composition according to claim 1~~ wherein the at least one poloxamer is poloxamer 188.

~~3~~2. The composition according to claim 1 ~~or 2~~ further comprising an intragranular filler, preferably selected from the group consisting of dicalcium phosphate, calcium sulfate, lactose, cellulose, kaolin, mannitol, sodium chloride starch and powdered sugar.

~~4~~3. The composition according to claim ~~3~~ 2 wherein the intragranular filler is mannitol, preferably in an amount of up to 80 % wt/wt, and more preferably in an amount of up to 40 % wt/wt.

~~5~~4. The composition according to any one of claims 1 to ~~4~~ 3 comprising from 20 to 50% wt/wt of the compound of formula (I) and from 20 to 40 % wt/wt of poloxamer 188.

~~6~~5. The composition according to claim ~~5~~ 4 comprising 40% wt/wt of the compound of formula (I) and 23% wt/wt of poloxamer 188.

~~7~~6. The composition according to claim ~~6~~ 5 comprising 40% wt/wt of the compound of formula (I), 23% wt/wt of poloxamer 188 and 37% wt/wt of mannitol.

~~8~~7. The composition according to claim 1 ~~or 2~~ being a binary composition consisting of a compound of formula (I) from 20 to 80% wt/wt and a poloxamer from 20 to 80% wt/wt, and preferably of a compound of formula (I) from 40 to 60% wt/wt and a poloxamer from 40 to 60% wt/wt.

~~9~~8. The composition according to any one of claims 1 to ~~8~~7 obtained by hot melt extrusion.

~~10~~9. The composition according to any one of claims 1 to ~~9~~8 wherein the compound of formula (I) is present in crystalline form.

~~11~~10. An oral dosage form comprising the composition of any one of claims 1 to ~~9~~8.

~~12~~11. The oral dosage form of claim ~~10~~9 further comprising at least one excipient selected from the group consisting of fillers, binders, disintegrants, lubricants, anti-adherents, glidants, colorants, polymer coatings and plasticizers.

~~13~~12. The oral dosage form of claim ~~10~~9 or ~~11~~10 being a tablet or capsule, preferably comprising an immediate release filmcoat.

~~14~~13. The composition according to any one of claims 1 to ~~10~~9 for use in the treatment of HCV infections.

~~15~~14. The use of a composition according to any one of claims 1 to ~~10~~9 in the manufacture of a medicament for the treatment of HCV infections.

~~16~~15. The oral dosage form according to any one of claims ~~11~~10 to ~~13~~12 for use in the treatment of HCV infections.